16.50
-22.28%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ACADIA Pharmaceuticals
From its filings with the US Securities and Exchange Commission
ACADIA Pharmaceuticals is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ACAD. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $1.07bn and net income of $391.0m. At that date it held total assets of $1.56bn and shareholders' equity of $1.23bn. By business, NUPLAZID brought in 63.5% of revenue, followed by DAYBUE at 36.5%.
We are a biopharmaceutical company focused on turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world.
We have two core franchises in neurological and rare diseases. Our neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). Our rare disease franchise is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Net product sales from these two commercial products totaled $1,071.5 million for 2025, compared with $957.8 million for 2024.
In addition to these commercial products, we have a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in neurological and rare diseases. In order to achieve significant long-term growth, we plan to develop our current portfolio, expand our pipeline of early- and late-stage product candidates and expand into areas of rare disease that are adjacent to our existing franchises, including through strategic business development, and make use of our internal capabilities and knowledge.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 27 May 2004
- Employees
- 653
- Website
- acadia-pharm.com ↗
- Head office
- 12830 EL CAMINO REAL, SAN DIEGO, CA, 92130
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Stephen BiggarIndependent Chairman of the Board$386,132
- Ms. Catherine Owen AdamsChief Executive Officer, Director, since 2024$7.6m
- Mr. Mark SchneyerChief Financial Officer, Executive Vice President$2.5m
- Ms. Jennifer RhodesExecutive Vice President, Company Secretary and Chief Legal Officer$3.3m
- Mr. Thomas GarnerExecutive Vice President, Chief Commercial Officer$3.7m
- Dr. Elizabeth ThompsonExecutive Vice President and Head of Research and Development$4.3m
- Mr. Scott CenciSenior Vice President, Chief Information and Data Officer
- Ms. Konstantina KatchevesSenior Vice President, Chief Business and Strategy Officer
- Ms. Allyson Mcmillan-YoungbloodSenior Vice President - Rare Disease Franchise
- Mr. Julian BakerIndependent Director$341,132
- Ms. Laura BregeIndependent Director$403,215
- Mr. James DalyIndependent Director$398,215
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 52
- Environment
- 16
- Social
- 99
- Governance
- 41
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ACADIA Pharmaceuticals Inc. has several strengths that contribute to its success:
Weaknesses
- ACADIA Pharmaceuticals Inc. also has some weaknesses that it needs to address:
Opportunities
- ACADIA Pharmaceuticals Inc. can capitalize on the following opportunities:
Threats
- ACADIA Pharmaceuticals Inc. should remain vigilant about potential threats:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.